Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants (Q44767199)

6 December 2017

title

Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants (English)

1 reference

6 December 2017

Jeffery W Kelly

1 reference

6 December 2017

Sean R Miller

1 reference

6 December 2017

Yoshiki Sekijima

series ordinal

1 reference

6 December 2017

publication date

1 May 2004

1 reference

6 December 2017

published in

Laboratory Investigation

1 reference

6 December 2017

1 reference

6 December 2017

1 reference

6 December 2017

page(s)

545-552

1 reference

Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Alternative conformations of amyloidogenic proteins govern their behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

The transthyretin-retinol-binding protein complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Fibril in senile systemic amyloidosis is derived from normal transthyretin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Prevention of transthyretin amyloid disease by changing protein misfolding energetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Rational design of potent human transthyretin amyloid disease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Therapeutic strategies for human amyloid diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Inhibiting transthyretin amyloid fibril formation via protein stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Inhibiting transthyretin conformational changes that lead to amyloid fibril formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

The chemistry, pharmacology and clinical pharmacology of diflunisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Trans-suppression of misfolding in an amyloid disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

Sequence Communication: Tabulation of transthyretin (TTR) variants as of 1/1/2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

7 January 2021

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

1 reference

7 January 2021

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

1 reference

7 January 2021

Thyroid hormone transport proteins.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

7 January 2021

Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

7 January 2021

Direct sequencing of the gene for Maryland/German familial amyloidotic polyneuropathy type II and genotyping by allele-specific enzymatic amplification

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

7 January 2021

Liver transplantation as a treatment for familial amyloidotic polyneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

7 January 2021

Homozygosity for the transthyretin-met30-gene in two Swedish sibs with familial amyloidotic polyneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

7 January 2021

Vitreous amyloidosis associated with homozygosity for the transthyretin methionine-30 gene

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

7 January 2021

Homozygosity for the met30 transthyretin gene in a Turkish kindred with familial amyloidotic polyneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

7 January 2021

Homozygosity for the transthyretin-Met30-gene in seven individuals with familial amyloidosis with polyneuropathy detected by restriction enzyme analysis of amplified genomic DNA sequences

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

7 January 2021

Homozygosity for the transthyretin-Met30 gene in three Japanese siblings with type I familial amyloidotic polyneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

7 January 2021

A case of familial amyloid polyneuropathy homozygous for the transthyretin Val30Met gene with motor-dominant sensorimotor polyneuropathy and unusual sural nerve pathological findings

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700059

7 January 2021

10.1038/LABINVEST.3700059

Identifiers

DOI

1 reference

6 December 2017

1 reference